Fact-checked by Grok 2 weeks ago

STAT

STAT is an digital news publication dedicated to in-depth reporting on , , , pharmaceuticals, and life sciences, launched on November 4, 2015, by through Globe Media as an independent venture. Operating from , it emphasizes fast-paced, that examines scientific advancements, industry dynamics, policy debates, and emerging threats, often from inside labs, boardrooms, and regulatory arenas. With a subscription-based model including its premium STAT+ service, the outlet has prioritized revenue from industry readers and professionals alongside general audiences, achieving financial stability rare in niche by its tenth anniversary in 2025. STAT gained prominence for early and prescient coverage of risks, notably being the first major U.S. outlet in 2020 to frame the as a potential catastrophic , shaping public and policy awareness amid initial skepticism from other institutions. Its investigative series, such as exposés on algorithmic denials of care by insurers like UnitedHealth and embedded biases in race-based medical algorithms, have earned accolades including finalist status and contributed to broader scrutiny of healthcare practices. The publication's business-oriented focus has supported robust original reporting, but it has also drawn praise for puncturing hype in biotech and pharma sectors. Despite its reputation for rigorous health journalism, STAT has faced criticisms over credibility lapses, including instances of undisclosed ties among contributors and conflicts of interest in pieces that favored certain corporate narratives without . Independent assessments rate it as generally reliable but left-center biased, particularly in editorial stances on issues like access and regulation, which may reflect broader institutional leanings and . These concerns underscore ongoing challenges in balancing ties with impartiality in specialized reporting.

History

Founding and Early Years

STAT was launched on November 4, 2015, by , principal owner of and the Boston Red Sox, along with his wife Linda Pizzuti Henry, as a standalone digital news organization under Boston Globe Media Partners. The venture aimed to address gaps in rigorous, independent journalism on , , , and life sciences, fields Henry identified as underserved amid rapid industry growth and public health implications. Unlike traditional advertising-dependent models, STAT adopted a subscription-based from , with initial pricing at $25 per month or $240 annually, to sustain investigative reporting by prioritizing reader revenue over advertiser influence. Henry's motivation crystallized during a 2014 dinner in discussing biomedical innovation, prompting him to invest approximately $10 million initially in building a specialized separate from The Boston Globe's broader operations. Rick Berke, a veteran journalist from and , joined as employee number one in early 2015 to recruit staff and shape editorial direction as co-founder and executive editor. The initial team comprised around 20 reporters and editors, many with expertise in science and , focused on delivering urgent, evidence-based coverage of clinical trials, , regulatory policy, and scientific breakthroughs. Early content emphasized accountability, such as scrutinizing pharmaceutical pricing and biotech ethics, positioning STAT as a niche player in an era of consolidating health media. In its first year, STAT grew to over 10,000 subscribers, validating the experiment while navigating challenges like distinguishing itself from trade publications and academic outlets often criticized for industry ties or ideological leanings. The outlet's name derived from the medical abbreviation for "immediately," reflecting its intent for timely, high-stakes reporting, with first articles covering topics like editing advancements and FDA approvals. By 2016, expansions included podcasts and opinion sections, but the core remained print-like depth in digital format, amassing awards for early investigations into crises and safety. This foundation established STAT's role in countering fragmented coverage, though its ties to —a data-driven —drew scrutiny over potential influences on biotech narratives.

Expansion and Milestones

Following its launch in late 2015, STAT rapidly scaled its operations, building a dedicated team of reporters focused on in-depth health and life sciences coverage, which grew to support expanded digital output including newsletters, videos, and special reports. By , the outlet had cultivated over 10,000 paying subscribers, with group subscriptions comprising 20% of its base and projected to increase by 67% the following year, reflecting a strategic emphasis on content diversification beyond reliance. Subscriber growth accelerated in subsequent years, surpassing 30,000 paid STAT+ members by September , contributing to annual revenue nearing $20 million and underscoring the viability of its subscription model in a . This expansion coincided with enhancements to its events portfolio, including the inaugural STAT Summit in 2020, which evolved into recurring virtual and in-person gatherings exploring biopharma innovations and policy. Further team buildouts, such as additions to science reporting and events staff, supported broader content ambitions amid rising demand for specialized analysis. Key milestones include sustained subscription momentum, with 30% annual growth over the two years leading to 2025, culminating in approximately 50,000 subscribers and a 10th reflection on transformative investigations like those on and origins. Recognition peaked with a 2024 Pulitzer Prize finalist nomination in Investigative Reporting for coverage of systemic issues in , affirming its influence despite a competitive landscape.

Ownership and Operations

Corporate Structure

STAT functions as an independent editorial unit within Boston Globe Media Partners, LLC, a privately owned media company controlled by , who serves as its principal owner and co-founder of STAT. Launched on November 4, 2015, STAT was established by Henry as a specialized and life sciences outlet, distinct from but integrated into the parent entity's operational framework, which includes shared administrative and revenue functions. This structure allows STAT to maintain a dedicated of approximately 100 members, headquartered in with bureaus in , , and , while leveraging Boston Globe Media's broader infrastructure for distribution and business operations. The company's governance is centralized under Boston Globe Media Partners, with no public board or shareholder disclosures typical of a private entity; ultimate decision-making authority resides with Henry, who acquired The Boston Globe in 2013 and expanded into niche verticals like STAT to target specialized audiences. Executive oversight for STAT falls to Co-founder and Executive Editor Rick Berke, responsible for editorial direction, under the supervision of Linda Henry, CEO of Boston Globe Media Partners since 2015, who handles corporate strategy including revenue growth and partnerships. Recent appointments, such as Vice President of Advertising & Revenue Operations Denise Thayer in September 2025, reflect efforts to enhance monetization through subscriptions—reaching over 30,000 paid subscribers and nearing $20 million in annual revenue by 2022—while preserving journalistic autonomy. In 2021, STAT's newsroom staff joined the , aligning with the parent company's unionized workforce and securing for wages, benefits, and working conditions across the shared corporate structure. This integration underscores STAT's position as a brand rather than a fully autonomous , enabling cost efficiencies but subjecting it to the financial and strategic priorities of , which reported supporting investments in STAT's expansion amid a niche focus on biotech, pharmaceuticals, and policy.

Leadership and Staff

Rick serves as co-founder and executive editor of STAT, a role he has held since the outlet's launch in , when he joined as its first employee to recruit and build the initial team focused on , , and life sciences . Prior to STAT, Berke spent over two decades at as a reporter and editor, including stints as chief political correspondent and national political editor, followed by a position as executive editor at . Under his leadership, STAT has emphasized rigorous, independent reporting on biomedical advancements, policy, and industry dynamics. The editorial structure includes managing editor Gideon Gil, who oversees daily operations and newsroom coordination; editorial director Laura Chang, responsible for strategic content direction; and news editor Amanda Erickson, handling breaking coverage and assignments. Additional key roles encompass Torie Bosch as editor of the First Opinion section, which features expert commentaries, and Alissa Ambrose as director of photography and multimedia, managing visual and digital storytelling elements. In April 2024, STAT elevated Zachary Tracer to senior editor for business and policy, tasking him with supervising coverage of , politics, and the economics of and pharmaceuticals. STAT's staff comprises approximately 100 employees as of September 2025, including specialized reporters across beats such as , , and policy, alongside editors, producers, and support personnel. Notable contributors include senior biotech writer Adam Feuerstein, whose reporting critically examines the intersection of Wall Street finance and pharmaceutical developments, drawing on over 16 years of experience in the sector; national biotech reporter Elaine Chen, co-author of the daily Readout newsletter; and cancer reporter Angus Chen, focusing on research and treatments. The team operates from bases in , , and other locations, enabling nationwide and global sourcing for stories.

Editorial Focus and Content

Core Topics and Approach

STAT's core coverage encompasses the intersections of , , , and , with a particular emphasis on the business dynamics of pharmaceuticals, , and life sciences innovation. Key topics include regulatory and legislative affecting and approval, hospital operations, challenges, and insurance mechanisms that shape access to care. The outlet prioritizes stories on scientific discoveries, industry strategies, experiences in clinical contexts, and disparities in medical outcomes, often drawing from labs, biotech firms, and arenas. In its editorial approach, STAT commits to "trusted, tough-minded " that involves original, in-depth reporting and exclusive analysis rather than superficial or consumer wellness advice. This manifests in features, trend pieces, and investigative accounts that provide context, timeliness, and insider perspectives, frequently incorporating interviews with experts, executives, and stakeholders to uncover strategies and implications in biotech and pharma sectors. The publication encourages pitches highlighting novel angles on timely developments, such as new findings or policy shifts, while avoiding embargoed studies unless they offer unique value. STAT supplements its news reporting with opinion content through sections like First Opinion, which solicits essays offering first-person perspectives, nuance to prevailing discourses, or challenges to conventional views in and . This format aims to foster debate on topics like clinical guidelines or industry , attributing viewpoints explicitly to authors rather than endorsing them editorially. Overall, the approach underscores by probing institutions and individuals in the health , supported by an editorial team experienced in specialized .

Notable Series and Investigations

STAT's "Denied by AI" series, published in 2023 by reporters Casey Ross and Bob Herman, scrutinized the deployment of AI algorithms by health insurers such as and to automate decisions, uncovering instances where the technology denied coverage for medically necessary treatments, potentially endangering patients with conditions like cancer and chronic illnesses. The reporting drew on internal documents, clinician interviews, and patient records to demonstrate error rates exceeding 20% in some AI-driven denials, prompting regulatory scrutiny from the U.S. Department of Health and Human Services. This work was named a 2024 finalist in Investigative Reporting and won the 2024 for investigative journalism. The "Health Care's Colossus" series, launched in 2024, examined UnitedHealth Group's dominance in the U.S. health care system through its Optum subsidiary's acquisition of over 2,000 physician practices since 2017, alleging that the insurer leveraged these networks to steer patients toward higher-cost procedures and inflate reimbursements, contributing to Medicare Advantage overpayments estimated at $12 billion annually by federal auditors. Based on leaked documents, financial analyses, and interviews with former executives, the series highlighted conflicts of interest where Optum physicians faced pressure to favor UnitedHealth-affiliated facilities. It received the 2024 National Institute for Health Care Management Foundation's Impact Award and recognition for excellence in national investigative reporting. Other investigations include a 2019 series on C treatment disparities in U.S. prisons, which revealed that fewer than 10% of eligible inmates received curative drugs despite federal mandates, leading to over 10,000 preventable deaths annually from liver complications; the reporting prompted lawsuits and policy reviews in states like and . STAT also exposed data security vulnerabilities at health tech startups in a 2022 probe, documenting breaches affecting millions of records due to lax encryption and third-party vendor risks. Additionally, in 2021, STAT investigated Biogen's accelerated FDA approval of the Alzheimer's drug Aduhelm, uncovering reliance on surrogate endpoints over clinical efficacy data and undisclosed communications with regulators, which fueled congressional hearings and coverage restrictions.

Impact and Reception

Achievements and Influence

STAT has garnered numerous accolades for its in and . In 2024, reporters Casey Ross and Bob Herman were finalists for the in Investigative Reporting for their series "Denied by AI," which examined the consequences of -driven algorithms in denying healthcare to vulnerable patients, including cases where pressured staff to override medical judgments based on the tool's outputs. The same series earned the 2024 Gerald for investigative reporting, recognizing its exposure of algorithmic biases affecting patient care decisions. Additionally, STAT's "Health Care's Colossus" series on 's physician empire and profit-driven practices won an award for excellence in national and international investigative reporting, along with an Impact Award from the Radio Television Digital News Association. In 2025, STAT received four from the Radio Television Digital News Association, the highest number among small digital news organizations, honoring outstanding achievements in electronic journalism across categories like investigative reporting and . Over its first decade since launching in 2015, the outlet has accumulated top honors in , science, and , including contributions to broader recognition of data-driven health inequities and biotech advancements. STAT's reporting has influenced debates and industry practices by highlighting systemic issues, such as inadequate hepatitis C treatment in U.S. prisons and vulnerabilities in health tech startups, prompting regulatory scrutiny and calls for reform. The "Denied by " investigation, for instance, amplified congressional inquiries into Medicare Advantage denials and insurer use of opaque algorithms, contributing to heightened oversight of in healthcare approvals. Similarly, the "Health Care's Colossus" series exposed UnitedHealth's expansion tactics, fueling antitrust discussions and public awareness of vertical integration's effects on care access and costs. In science journalism, STAT has elevated specialized coverage of life sciences, biotech , and medical innovation, serving as a key resource for policymakers, researchers, and executives through exclusive insights into and power dynamics. Its election-year analyses delineated candidate stances on , aiding informed discourse amid polarized debates on topics like drug pricing and funding. By prioritizing rigorous, data-backed narratives over , STAT has sustained a niche model in a challenging media landscape, demonstrating viability for focused reporting.

Criticisms and Bias Claims

STAT News has faced accusations of left-center bias in its coverage of and medical issues, with rating it as such due to editorial positions that moderately favor stances, such as support for expanded government involvement in healthcare and skepticism toward market-driven pharmaceutical innovations. quantifies this as a mild left-leaning score of -2.55 on a from -42 (extreme left) to +42 (extreme right), while assigning a reliability score of 44.11 out of 64, indicating generally factual reporting mixed with occasional analysis. In contrast, rates STAT as overall, based on feedback and blind bias surveys showing balanced perspectives, though some reviewers perceive a slight left tilt. Critics have highlighted potential pharmaceutical industry influence undermining STAT's independence, despite its nonprofit structure and editorial firewalls. In March 2018, reports emerged of articles published by STAT featuring authors with undisclosed financial ties to drug companies, including content from industry sources, which raised questions about and objectivity in biotech coverage. Statistician documented a 2022 case involving STAT reporter Herper, who maintained paid consulting roles with pharmaceutical firms while covering topics, potentially creating incentives to favor positive narratives on over rigorous scrutiny of conflicts or failures. Gelman argued this reflects broader vulnerabilities in , where access to insiders can subtly shape reporting without overt bias, as evidenced by STAT's reluctance to fully disclose such arrangements. These pharma-related concerns persist amid STAT's reliance on advertising revenue from biotech and healthcare sectors, which some analysts claim encourages uncritical amplification of corporate releases disguised as , particularly on high-stakes topics like approvals and outcomes. STAT's ethics policy mandates of conflicts and avoidance of public controversies unrelated to its beat, yet enforcement has been questioned in instances where reporters' external affiliations aligned with covered entities. No major retractions or regulatory probes have resulted from these issues, but they have fueled among industry watchdogs regarding STAT's ability to maintain impartiality in an ecosystem dominated by stakeholder funding.

Controversies

Coverage Disputes

STAT News has encountered disputes over the integrity of its opinion content, particularly regarding undisclosed financial ties to the in contributed pieces. In 2017, an by Dr. Robert Yapundich defending pharmaceutical sales representatives was revealed to have been ghostwritten by Keybridge Communications, a firm with pharmaceutical clients, after Yapundich received over $200,000 from companies; STAT retracted the piece following public scrutiny. Similarly, a 2017 article by defending vaccines omitted disclosure of his $45 million in royalties from Merck's , prompting criticism for lacking transparency in a outlet focused on debates. These incidents highlighted concerns about industry influence in STAT's platform, given the outlet's emphasis on biotech and coverage, where pharmaceutical permeates academic and ecosystems. Further contention arose in 2018 when an by criticizing NIH funding for drew attention to his prior ghostwritten Forbes contributions for , undisclosed at the time, raising questions about selective affiliations in pro-industry . In response to such cases, including a 2016 praising Gilead's hepatitis C ads that originated from the company's firm, STAT revised its policies in 2017 to mandate conflict disclosures and prohibit submissions from or groups. Critics, including professor Charles Seife, argued these measures were insufficient, as pharma's opaque practices continued to infiltrate . A 2021 op-ed by William S. Smith opposing Biden administration drug pricing evaluations omitted his decade-long role as 's vice president of public affairs and policy, as well as ties to the Pioneer Institute, which receives funding; transparency advocates like Till Bruckner condemned the non-disclosure, echoing prior HealthNewsReview critiques of STAT's vetting since 2017. STAT's reliance on industry-adjacent contributors has fueled broader claims of pro-pharma bias, with statistical blogger noting in 2022 that such lapses compromise the outlet's credibility in an arena prone to financial incentives over impartial analysis. Disputes have also emerged in STAT's reporting on origins, where a 2024 opinion piece labeled the lab leak "evidence-free" and harmful to , despite U.S. intelligence assessments from agencies like the FBI and Department of Energy deeming it plausible with moderate confidence based on of Wuhan Institute of Virology research risks. This stance drew criticism from proponents of the theory, who argue it reflects institutional reluctance to scrutinize gain-of-function experiments funded by U.S. agencies, potentially prioritizing zoonotic narratives aligned with mainstream academic consensus over emerging data. Media bias evaluators rate STAT as left-center on , with high factual accuracy but editorial leanings that may undervalue dissenting empirical indicators in politically charged topics.

Ethical and Reporting Issues

STAT News has faced criticism for lapses in disclosing conflicts of interest in opinion pieces, particularly those involving ties, which undermine and raise questions about oversight in a field heavily influenced by corporate funding. In response to these incidents, primarily occurring between 2016 and 2018, the outlet implemented stricter disclosure requirements for contributors, including queries about industry payments and affiliations. These cases highlight broader challenges in , where undisclosed financial relationships can introduce favoring industry perspectives, though STAT's news reporting has not been implicated in similar fabrication or error scandals. Notable examples include a 2016 op-ed by patient advocate Deborah Clark Dushane praising direct-to-consumer drug advertisements for C treatments, which was with assistance from a firm hired by ; the industry connection was not initially disclosed and only revealed in 2017. Similarly, a 2017 piece by Robert Yapundich defending pharmaceutical sales representatives was by Keybridge Communications, a firm with pharma clients, and retracted after discrepancies emerged; Yapundich had received over $200,000 from drug companies, undisclosed at publication. Another instance involved a February 2018 op-ed by criticizing funding for , where Miller's prior dismissal from for undisclosed Monsanto ghostwriting was not mentioned. Additional concerns arose from a 2017 response by pediatrician to vaccine skeptic , omitting Offit's financial stake in Merck vaccine royalties estimated at $45 million, and a pro-opioid from the American Council on and Health without revealing its industry funding. In 2021, an by William S. Smith critiquing the Biden administration's drug evaluation plans via for Clinical and Economic Review failed to disclose Smith's decade as Pfizer's vice president of public affairs and policy, or the think tank's support, prompting accusations of echoing industry arguments without transparency. Critics, including transparency watchdogs, argued these oversights breached trust, especially given STAT's focus on biotech and pharma, where such affiliations could skew advocacy for looser regulations or higher drug pricing. While STAT maintains an ethics policy prohibiting staff from public controversies unrelated to its beat and emphasizing source independence, the op-ed incidents exposed gaps in vetting external contributors, contrasting with the outlet's investigative work on conflicts elsewhere. No systemic retractions of STAT's core articles have been documented, and searches for errors yield no major scandals, though the outlet's left-center rating—favoring progressive stances on —has drawn separate scrutiny for potentially underemphasizing market-driven critiques in pharma coverage. These issues underscore the tension between STAT's mission to illuminate frontiers and the risk of capture in opinion content, prompting calls for rigorous, upfront vetting to preserve credibility.

References

  1. [1]
    STAT | Boston Globe Media
    STAT's award-winning newsroom delivers trusted, authoritative, and indispensable insights and exclusive stories on the technologies, personalities, power ...
  2. [2]
    STAT News
    Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.About Us - STAT health, life ...HealthLatest health, science and ...The STAT TeamNewsletters
  3. [3]
    STAT - LinkedIn
    Reporting from the frontiers of health and medicine. We take you inside the science labs and hospitals, biotech boardrooms and political backrooms.
  4. [4]
    On its 10th anniversary, health care site STAT is flourishing - Poynter
    Sep 9, 2025 · STAT, a health care, medicine and biotech news site, marks its 10th anniversary this week with plenty to celebrate.
  5. [5]
    Stat's 10-Year History Coupling Quality Reportage With Paid Subs
    Jun 26, 2025 · Stat launched 10 years ago out of Boston Globe Media to cover health, medicine and the life sciences with an unabashed focus on generating revenue directly ...
  6. [6]
    STAT Marks 10 Years of Reporting from the Frontiers of Health and ...
    Sep 9, 2025 · 2020 – STAT was the first U.S. news organization to seize on the novel coronavirus as a potentially catastrophic global health threat, and ...
  7. [7]
    Denied by AI: STAT series honored as 2024 Pulitzer Prize finalist
    Casey Ross and Bob Herman report on how UnitedHealth Group used an unregulated algorithm to deny care to seriously ill older and disabled patients.
  8. [8]
    Discover the Embedded Bias series - STAT News
    STAT series 'Embedded Bias' explores how race-based clinical algorithms became pervasive in medicine, and why racial factors have been difficult to remove.
  9. [9]
    STAT News Officially Has a Credibility Problem
    Mar 16, 2018 · STAT News is the latest independent publication to be haunted by pharmaceutical ghostwriting and authors with undisclosed industry ties.
  10. [10]
    Troubling conflict of interest at Stat News
    May 30, 2022 · STAT delivers some terrific journalism. But in the interest of continuous quality improvement, it should re-examine its op-ed and broader conflict of interest ...
  11. [11]
    Stat (News) - Bias and Credibility - Media Bias/Fact Check
    We rate Stat News Left-Center biased based on editorial positions that moderately favor the left on political health and medical issues.
  12. [12]
    Stat News Bias and Reliability | Ad Fontes Media
    The following are the overall bias and reliability scores for Stat News according to our Ad Fontes Media ratings methodology. Reliability: 44.11. Bias: -2.55.
  13. [13]
    'Boston Globe' Owner Launches 'Stat News' Site Covering Life ...
    Nov 4, 2015 · The billionaire owner of the Boston Globe, John Henry, launched Stat Wednesday, a separate digital newsroom devoted to covering life sciences.Missing: early | Show results with:early
  14. [14]
    Why Boston Globe owner John Henry started STAT - STAT News
    Nov 4, 2015 · My decision to create a new publication about health, medicine, and life sciences began to take shape during a dinner I attended in Boston ...Missing: history | Show results with:history
  15. [15]
    Why STAT is the media startup to envy - Columbia Journalism Review
    Feb 23, 2016 · STAT exists as an independent company from the Globe, making its own editorial decisions and publishing on its own terms, but the paper benefits ...
  16. [16]
    Rick Berke - STAT News
    Rick Berke is the co-founder and executive editor of STAT. He moved to Boston in early 2015 as STAT's Employee #1, charged with assembling a world-class staff.
  17. [17]
    About Us - STAT health, life science, medicine and biotech news
    STAT was launched in 2015 by John Henry, the owner of the Boston Globe, and is part of Boston Globe Media. Its mission was to cover not only the life sciences ...Missing: history | Show results with:history
  18. [18]
    Our Name - STAT News
    Its first common usage as a medical term appeared in 1875, in William Handsel Griffiths' seminal (or not) text: “Lessons on Prescriptions and the Art of ...Missing: founding | Show results with:founding
  19. [19]
    With over 10000 paying subscribers, Stat News focuses on ... - Digiday
    Dec 2, 2019 · Groups accounted for 20% of Stat's subscriptions in 2019, and Stat expects its group subscriber base to grow 67% in 2020, Macaulay said. Overall ...
  20. [20]
    Stat Tops 30,000 Subscribers, Nears $20 Million in Revenue
    Sep 2, 2022 · Its paid membership program, Stat+, now counts more than 30,000 subscribers paying either $39 per month or $399 per year, according to the ...
  21. [21]
    STAT Summit 2020
    This virtual event was hosted online from Nov. 16-19, 2020. Each day started at 1 p.m. ET, and programming explored the development of new medicines and ...
  22. [22]
    STAT expands science and events team
    STAT, the nation's leading health, science and medicine publication, today announced the expansion of its reporting and events teams.
  23. [23]
    10 times STAT coverage reverberated through health and medicine
    Sep 9, 2025 · As STAT turns 10, a look at our milestone stories: Purdue Pharma secrets, UnitedHealth denials, hepatitis in prisons, Covid pandemic ...
  24. [24]
    Award-winning coverage, health and life sciences - STAT News
    See the honors and accolades for our health, medicine and science news. STAT was a 2024 Pulitzer Prize Finalist in Investigative Reporting.
  25. [25]
    The STAT Team
    Alissa Ambrose. Director of Photography and Multimedia ; Torie Bosch. Editor, First Opinion ; Laura Chang. Editorial Director ; Amanda Erickson. News Editor ...Rick Berke · Elizabeth Cooney · Gideon Gil, Managing EditorMissing: structure | Show results with:structure
  26. [26]
    The Globe's Stat goes union - Media Nation
    Mar 26, 2021 · “Having STAT workers become part of the Guild means a stronger voice. We all work within the structure of the Boston Globe Media Partners and we ...<|separator|>
  27. [27]
    Rick Berke - Boston Globe Media
    Rick Berke is executive editor at STAT. As its first employee, he assembled a world-class staff to cover health, medicine and the life sciences.
  28. [28]
    Richard L. Berke's Biography - Muck Rack
    Rick Berke, executive editor, oversees STAT's editorial team. He was previously a longtime reporter and editor at The New York Times, where he served as ...
  29. [29]
    Rick Berke - Co-founder & Executive Editor STAT - LinkedIn
    Rick Berke. Co-founder & Executive Editor STAT | News Reporting, Editorial, Digital Content. Statnews.com Columbia University - Graduate ...
  30. [30]
    A letter from the executive editor: STAT turns 10
    Virtually STAT's entire team of reporters has been covering how President Trump and his administration are transforming the federal ...
  31. [31]
    STAT announces new leadership positions
    Apr 18, 2024 · Zachary Tracer is joining STAT as senior editor, business & policy. He will oversee our policy and political reporters, as well as our business of health care ...
  32. [32]
    Adam Feuerstein - Senior Writer, STAT News | LinkedIn
    I write about the intersection of biotech and Wall Street. I've been covering this beat for 16 years, first at TheStreet and now at STAT.
  33. [33]
    Elaine Chen, National Biotech Reporter - STAT News
    Elaine Chen is a national biotech reporter at STAT. She co-writes The Readout newsletter and co-hosts The Readout Loud podcast.Missing: members | Show results with:members
  34. [34]
    Angus Chen, Cancer Reporter - STAT News
    Angus Chen is a cancer reporter at STAT. He was previously a reporter at WBUR and NPR, covering health and science.Missing: members | Show results with:members
  35. [35]
    STAT hires two new D.C. reporters
    STAT, the leading news source for tough-minded coverage of health, medicine, and the life sciences, has added two reporters to its Washington, DC team.
  36. [36]
    Pitch guidelines for freelance science and health writers - STAT News
    Freelancers, start here: STAT is looking for compelling, original reporting on health, medicine, and scientific discovery.Missing: core approach
  37. [37]
    [PDF] Founded in 2015, STAT is a national media
    We focus on exclusive, deeper dives into breaking news, and include educated perspectives and POVs from an editorial staff with decades of experience in the ...
  38. [38]
    Guidelines for writing and submitting essays to First Opinion | STAT
    It should challenge popular opinion, add nuance, or add a first-person perspective that is missing from the discourse.Missing: core | Show results with:core
  39. [39]
    STAT “Denied by AI” series a model of solid investigative journalism
    Oct 21, 2024 · The series detailed the dangers of using an AI-driven algorithm to assist doctors and insurance case managers in patient decision-making.
  40. [40]
    Finalist: Casey Ross and Bob Herman of STAT - The Pulitzer Prizes
    As the Pulitzer Prizes honor categories of journalism, arts, and letters, we mark the loss of invaluable records of the human experience. See all 2024 winners ...
  41. [41]
    STAT wins 2024 Loeb Award for investigative reporting
    Oct 10, 2024 · STAT reporters Casey Ross and Bob Herman won the 2024 investigative prize from the Loeb Awards for "Denied by AI: Consequences for Sick and ...
  42. [42]
    Health Care's Colossus: Investigative series on UnitedHealth Group
    A STAT investigative series looking at how UnitedHealth Group wields its unrivaled physician empire to boost profits, expand influence. fuel growth.
  43. [43]
    A STAT Investigation: Health, Science and Medicine Issues
    STAT Plus: Hospitals get dinged for reporting too many infections. · STAT Plus: Staff cuts are undermining federal research on how to make health care better.
  44. [44]
    STAT Marks 10 Years of Reporting from the Frontiers of Health and ...
    Sep 9, 2025 · Founded by John and Linda Henry, the owners of The Boston Globe, STAT was meant to test the idea that readers would pay for high quality, in- ...<|separator|>
  45. [45]
    Letter from STAT editor: A seminal moment for science journalism
    Nov 7, 2024 · They gave readers expert coverage during the campaign that clearly delineated the health policy differences between Kamala Harris and Trump ...Missing: impact | Show results with:impact
  46. [46]
    STAT - AllSides
    On average, those who disagree with our rating think this source has a Center bias. Confidence Level. Confidence is determined by how many reviews have been ...
  47. [47]
    STAT's Ethics Policy - STAT News
    You should avoid weighing in on any public controversies, even foreign conflicts and other matters seemingly remote from what STAT and you cover; virtually any ...
  48. [48]
    Open Letter to STAT: It's Time for Strong, Clear COI Disclosure Policies
    Feb 28, 2018 · “Big pharma's attempt to ghostwrite in STAT ended badly – but not badly enough,” pointed out journalism professor Charles Seife in Slate. “STAT ...
  49. [49]
    https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
  50. [50]
    The coronavirus lab leak hypothesis is damaging science
    Aug 2, 2024 · Promoting the evidence-free lab leak hypothesis of Covid's origin could hold back the development of antiviral agents in the U.S..
  51. [51]
    https://www.statnews.com/2016/03/21/drug-ad-hepatitis/
  52. [52]
    https://www.statnews.com/2017/09/01/doctor-pharma-sales-reps/
  53. [53]
    https://www.statnews.com/2018/02/26/alternative-medicine-nih-funding/
  54. [54]
    https://www.statnews.com/2017/08/21/robert-kennedy-vaccines-question-answer/
  55. [55]
    https://www.statnews.com/2021/02/09/biden-administration-look-beyond-icer-drug-evaluation/